Technical Analysis for ACUR - Acura Pharmaceuticals, Inc.
|Grade||Last Price||% Change||Price Change|
ACUR closed down 1.82 percent on Friday, June 23, 2017, on 46 percent of normal volume. It was able to find support at its 50 day moving average. The price action carved out a bullish hammer (or hammer-like) candlestick pattern. That may indicate an upside reversal. Look for price to trade above the high of the hammer for confirmation. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.
Trend Table & Recent Alerts
|Weak or Absent||Down||Up||Up|
|See historical ACUR trend table...|
|Date||Alert Name||Type||% Chg|
|Jun 23||50 DMA Support||Bullish||0.00%|
|Jun 23||Hammer Candlestick||Bullish||0.00%|
|Jun 23||Stochastic Reached Overbought||Other||0.00%|
|Jun 23||Bollinger Band Squeeze||Range Contraction||0.00%|
|Jun 22||Crossed Above 50 DMA||Bullish||-1.82%|
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
- Earnings date: 2017-05-15
Acura Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the research, development, and commercialization of product candidates intended to address medication abuse and misuse utilizing its proprietary Aversion and Impede technologies. Its products include Oxecta Tablets CII, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed, an over-the-counter immediate-release pseudoephedrine HCl tablet that is used as a nasal decongestant in various non-prescription and prescription cold, sinus, and allergy products. The company has seven additional opioid products utilizing Aversion technology in various stages of development. Acura Pharmaceuticals, Inc. has a license, development, and commercialization agreement with King Pharmaceuticals Research and Development, Inc., a wholly-owned subsidiary of Pfizer Inc. to develop and commercialize certain opioid analgesic products utilizing the company's proprietary Aversion technology in the United States, Canada, and Mexico. The company was founded in 1935 and is based in Palatine, Illinois.
Is ACUR a Buy, Sell or Hold?
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more ACUR news...
|52 Week High||2.18|
|52 Week Low||0.401|
|200-Day Moving Average||0.8214|
|50-Day Moving Average||0.5249|
|20-Day Moving Average||0.5169|
|10-Day Moving Average||0.5264|
|Average True Range||0.0368|
|Chandelier Exit (Long, 3 ATRs)||0.4496|
|Chandelier Exit (Short, 3 ATRs)||0.5604|
|Upper Bollinger Band||0.5508|
|Lower Bollinger Band||0.483|
|Percent B (%b)||0.84|
|MACD Signal Line||-0.0005|